Microglial Dysfunction in Alzheimer's Disease

Microglial Dysfunction in Alzheimer's Disease

The microglial dysfunction hypothesis represents a critical paradigm shift in understanding Alzheimer's disease (AD) pathogenesis. Traditionally viewed as a secondary inflammatory response to amyloid-beta (Aβ) deposition, microglia are now recognized as central drivers of neurodegeneration through their dysregulated functions in immune surveillance, synaptic pruning, and metabolic support.

Overview

Microglial Dysfunction in Alzheimer's Disease

The microglial dysfunction hypothesis represents a critical paradigm shift in understanding Alzheimer's disease (AD) pathogenesis. Traditionally viewed as a secondary inflammatory response to amyloid-beta (Aβ) deposition, microglia are now recognized as central drivers of neurodegeneration through their dysregulated functions in immune surveillance, synaptic pruning, and metabolic support.

Overview

Microglia are the resident immune cells of the central nervous system (CNS), derived from yolk sac progenitors that colonize the brain during embryonic development["@ginhoux2010"]. These cells constitute approximately 5-10% of the adult brain cell population and serve as the primary defense against pathogens, injury, and metabolic stress["@aguzzi2013"]. In AD, microglia undergo profound phenotypic changes that impair their protective functions while paradoxically amplifying neurotoxic inflammation.

The microglial dysfunction hypothesis posits that age-related or genetic factors cause microglia to enter a maladaptive state characterized by:

• Chronic pro-inflammatory activation
• Impaired Abeta clearance
• Dysregulated synaptic pruning
• Metabolic dysfunction
• Loss of homeostatic functions["@deczkowska2020"]

TREM2 and TYROBP Signaling Pathway

TREM2 Structure and Function

Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane receptor expressed exclusively on microglia in the brain[@colonna2000]. It belongs to the immunoglobulin superfamily and partners with the adaptor protein TYROBP (also known as DAP12) to transduce extracellular signals into cellular responses[@lanier2009].

TREM2 possesses an extracellular ligand-binding domain, a transmembrane helix, and a cytoplasmic tail that interacts with TYROBP's immunoreceptor tyrosine-based activation motif (ITAM)[@kober2016]. Upon ligand binding, SYK kinase is recruited and activated, triggering downstream signaling cascades involving PLCγ, CARD9, and NF-κB[@peng2010].

TREM2 Ligands

Several ligands have been identified for TREM2:

• Apolipoprotein E (ApoE): TREM2 binds to lipidated ApoE, which is heavily produced by microglia in response to injury[@atagi2015]
• Amyloid-beta: Aβ oligomers and fibrils can engage TREM2, providing a direct link between amyloid pathology and microglial activation[@zhao2018]
• Phospholipids: Exposed phospholipids on apoptotic cells serve as danger-associated molecular patterns (DAMPs)[@canton2014]
• TREM2 ligands from neurons: Neuronal activity may release TREM2 ligands that modulate microglial function[@wu2019]

TYROBP (DAP12) Adaptor Protein

TYROBP is a transmembrane adaptor protein containing an ITAM that becomes phosphorylated upon TREM2 activation[@barrett2012]. The TREM2-TYROBP complex activates:

• SYK kinase: Central kinase downstream of ITAM phosphorylation[@mcsai2010]
• PI3K/AKT pathway: Promotes cell survival and metabolic function[@orr2017]
• MAPK signaling: Regulates gene expression and inflammatory responses[@lee2018]
• NF-κB activation: Controls pro-inflammatory cytokine transcription[@gao2016]

TREM2 Variants and AD Risk

Rare coding variants in TREM2 significantly increase AD risk, with the R47H variant conferring approximately 3-fold increased odds[@guerreiro2013]. This variant impairs TREM2's ability to bind its ligands, particularly ApoE and Aβ, demonstrating the critical role of microglial immune sensing in AD pathogenesis[@jonsson2013].

Other TREM2 risk variants include:

• R62H: Associated with moderate AD risk increase[@rayapudi2016]
• D87N: Loss-of-function variant linked to enhanced disease susceptibility[@cheng2018]
• Y38C: Impaired signaling capacity[@song2019]

Disease-Associated Microglia (DAM)

DAM Phenotype

The Disease-Associated Microglia (DAM) program represents a distinct microglial transcriptional state activated in response to neurodegeneration[@krasemann2017]. DAM cells are characterized by upregulation of genes involved in:

• Phagocytosis: CD68, C1qa, C1qb, Hexosaminidase subunit beta (HEXB)[@sierra2013]
• Lipid metabolism: Apolipoprotein E (APOE), Lipoprotein lipase (LPL)[@huang2018]
• 炎症反应: Trem2, Tyrobp, Clec7a[@matsuda2020]
• Iron handling: Ferritin heavy chain (FTH1), Ferritin light chain (FTL)[@liddelow2017]

DAM Stages

The DAM program develops in a two-stage progression:

Stage 1 (TREM2-independent): Initial activation characterized by upregulation of Type I interferon-responsive genes and gradual upregulation of some DAM genes. This stage occurs even in the absence of functional TREM2[@krasemann2017a].

Stage 2 (TREM2-dependent): Full DAM differentiation requires TREM2 signaling. This stage involves dramatic upregulation of phagocytic genes, lipid metabolism genes, and genes involved in lysosomal function[@wang2020].

Microglial Clusters in AD

Single-cell RNA sequencing has revealed multiple microglial subpopulations in AD brain tissue[@mathys2019]:

• Cluster 1: Age-related microglia (ARM) - associated with aging rather than disease[@olah2018]
• Cluster 2: Inflammatory microglia - expressing high levels of IL1B, CCL2, and other pro-inflammatory mediators[@crotti2019]
• Cluster 3: Aβ-responsive microglia - specifically upregulated in proximity to amyloid plaques[@sala2019]
• Cluster 4: Neural microglia - expressing synaptic function-related genes[@li2020]

Neuroinflammation Feedback Loops

Chronic Microglial Activation

In AD, microglia become trapped in a chronic pro-inflammatory state characterized by sustained production of:

• Interleukin-1β (IL-1β): Drives neuronal stress response and promotes tau pathology[@sheng2003]
• Tumor necrosis factor-α (TNF-α): Induces synaptic dysfunction and neuronal death[@mccoy2006]
• Interleukin-6 (IL-6): Impairs neurogenesis and promotes Aβ production[@spooren2010]
• CCL2/MCP-1: Recruits additional inflammatory cells and promotes neurotoxicity[@conductier2010]

Amplification Loops

Aβ-IL-1β Loop: Aβ deposition triggers microglial IL-1β production, which in turn increases amyloid precursor protein (APP) expression and Aβ generation by neurons[@rogers2011].

Tau-IL-1β Loop: IL-1β promotes tau hyperphosphorylation and propagation, while tau aggregates can activate microglia through TREM2-independent pathways[@ghosh2019].

NLRP3 Inflammasome: Microglial NLRP3 activation by Aβ creates a self-amplifying inflammatory cascade that drives chronic neuroinflammation[@heneka2013].

Microglial-Neuronal Cross-Talk

Dysfunctional microglia lose their ability to support neuronal health:

• Impaired synaptic pruning: Microglial complement proteins (C1q, C3) tag synapses for elimination, but dysregulated pruning in AD leads to excessive synapse loss[@stephan2013]
• Growth factor deprivation: Microglia normally produce BDNF and other trophic factors; this function is lost in the DAM state[@mott2018]
• Ion homeostasis: Microglial dysfunction contributes to extracellular K+ accumulation and neuronal hyperexcitability[@zhang2020]

Therapeutic Implications

TREM2-Targeting Strategies

Several therapeutic approaches target the TREM2 pathway:

• TREM2 agonistic antibodies: Activate TREM2 signaling to promote microglial Aβ clearance[@schlepckow2020]
• TREM2 decoy receptors: Soluble TREM2 (sTREM2) may have protective functions[@surezfarias2021]
• Small molecule TREM2 activators: Currently in development[@cignarella2020]

Anti-inflammatory Approaches

• CSF1R antagonists: Deplete dysfunctional microglia while allowing replacement with healthy cells[@elmore2018]
• NLRP3 inhibitors: Target the inflammasome-driven inflammatory cascade[@coll2015]
• Minocycline: Broad-spectrum anti-inflammatory effects on microglia[@familian2007]

Microglial Metabolism in AD

Metabolic Reprogramming

AD-associated microglia undergo dramatic metabolic changes that impair their function[@baik2019]. Under normal conditions, microglia rely primarily on oxidative phosphorylation (OXPHOS) for energy production. However, in the DAM state, microglia shift toward aerobic glycolysis, a metabolic program typically associated with immune activation[@lauro2020].

This metabolic shift has several consequences:

• Lactate accumulation: Increased glycolysis leads to lactate production, which can acidify the extracellular environment and promote neuronal dysfunction[@sewell2014]
• Impaired OXPHOS: Mitochondrial function becomes compromised, reducing ATP production capacity[@gao2019]
• NAD+ depletion: Rapid consumption of NAD+ in glycolysis disrupts cellular homeostasis[@johnson2018]

Lipid Metabolism Dysregulation

Microglia in AD show profound alterations in lipid metabolism[@zhang2020a]. The TREM2 pathway is intimately connected to lipid handling:

• Cholesterol accumulation: Foam cell formation in AD microglia mirrors atherosclerotic plaque development[@brites2014]
• Oxidized lipids: Accumulation of oxidized phospholipids serves as a DAM trigger[@linker2018]
• Eicosanoid production: Pro-inflammatory eicosanoids amplify neuroinflammation[@joshi2019]

Mitochondrial Dysfunction

Mitochondrial abnormalities in AD microglia include:

• Mitochondrial fragmentation: Increased DRP1-mediated fission impairs mitochondrial quality control[@kaur2017]
• Reduced mtDNA copy number: Depleted mitochondrial DNA compromises OXPHOS capacity[@cai2018]
• Accumulation of mutant mtDNA: Clonal expansion of mutant mitochondria in affected brain regions[@weber2020]

Research Directions and Future Perspectives

Single-Cell Technologies

Advanced single-cell approaches are revealing unprecedented detail about microglial heterogeneity in AD[@masuda2020]:

• Spatial transcriptomics: Mapping gene expression in situ reveals microglial states in relationship to pathology[@chen2021]
• Single-cell ATAC-seq: Chromatin accessibility profiling identifies regulatory elements controlling DAM programs[@liu2021]
• Multi-omics integration: Combining transcriptomics, proteomics, and epigenomics provides holistic understanding[@chen2022]

Microglial Replacement Therapies

Emerging strategies aim to replace dysfunctional microglia with healthy cells[@bennett2020]:

• Bone marrow transplantation: Hematopoietic stem cell therapy shows promise in preclinical models[@manczak2019]
• Induced microglia-like (iMG) cells: Patient-derived iMG cells offer personalized therapeutic potential[@cocozza2020]
• Microglial stem cell therapy: Pluripotent stem cell-derived microglia for transplantation[@speicher2021]

Biomarker Development

Microglial biomarkers are being developed for AD diagnosis and monitoring[@henriksen2019]:

• sTREM2 in CSF: Soluble TREM2 levels correlate with disease progression[@ewers2020]
• PET ligands: Microglial activation imaging with TSPO-PET reveals inflammatory burden[@hamelin2016]
• Blood biomarkers: Peripheral immune markers reflect CNS microglial activation[@surendranathan2020]

Conclusion

The microglial dysfunction hypothesis has transformed our understanding of AD pathogenesis by positioning microglia as central drivers rather than passive responders to pathology. The TREM2-TYROBP signaling pathway provides a molecular bridge connecting genetic risk factors to microglial dysfunction, while the DAM program reveals the complex phenotypic changes that characterize disease-associated microglial states. Understanding the neuroinflammation feedback loops that perpetuate microglial dysfunction, coupled with insights into metabolic reprogramming, offers promising therapeutic targets for disease-modifying interventions in AD. The emergence of single-cell technologies and microglial replacement therapies heralds a new era of precision immunology approaches to neurodegeneration.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References